Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Cortical neuron atrophy is a hallmark of depression and includes neurite retraction, dendritic spine loss, and decreased synaptic density. Psychoplastogens, small molecules capable of rapidly promoting cortical neuron growth, have been hypothesized to produce long-lasting positive effects on behavior by rectifying these deleterious structural and functional changes. Here we demonstrate that ketamine and LSD, psychoplastogens from two structurally distinct chemical classes, promote sustained growth of cortical neurons after only short periods of stimulation. Furthermore, we show that psychoplastogen-induced cortical neuron growth can be divided into two distinct epochs: an initial stimulation phase requiring TrkB activation and a growth period involving sustained mTOR and AMPA receptor activation. Our results provide important temporal details concerning the molecular mechanisms by which next-generation antidepressants produce persistent changes in cortical neuron structure, and they suggest that rapidly excreted psychoplastogens might still be effective neurotherapeutics with unique advantages over compounds like ketamine and LSD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their effects seem to be Cmax driven, as very short stimulation periods (15 min−1 h) are sufficient to induce sustained changes in cortical neuron structure (153)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Though the primary molecular targets of ketamine and serotonergic psychedelics are distinct, their downstream pharmacology overlaps, requiring AMPA receptor, TrkB, and mTOR activation to elicit changes in neuronal structure and function (135–137, 148, 153, 154).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [153]
The cited source says what the claim attributes to it.
In the citing paper
“An exceedingly short stimulation period (<1 h) is sufficient for psychoplastogens to activate cortical neuron growth mechanisms that can last for several days (153).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [153]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795
Cited by
Items 101–141 of 141
Chagraoui, A., Kaźmierska, P., Byache, O., Abraham, A., Rudin, D., Caban, B., Kowalczyk, T., Liechti, M. E., Wacker, D., Aman, C., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117799 · Cited by 2
Allen, J., Jupp, B., Baker, T. L., Haskali, M. B., Brkljača, R., Plummer, Z., Sun, M., Brand, J., Christie, B. R., Debert, C. T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102867 · Cited by 2
Understanding ketamine subjective effects
Dahan, A., & Niesters, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00008-4 · Cited by 1
Stupak, R. (2025) · Praktyka Teoretyczna · doi:10.19195/prt.2025.2.9 · Cited by 1
The Use of Psychedelics in the Treatment of Adult ADHD: A Systematic and Mechanistic Review
Chmiel, J., Malinowska, A., & Kurpas, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083453 · Cited by 1
Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats
Bysiek, A., Szpręgiel, I., Wojtas, A., Maćkowiak, M., Wawrzczak‐Bargieła, A., Leśkiewicz, M., Trojan, E., Kamińska, K., Kumorek, W., Bilecki, W., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111710 · Cited by 1
Synthesis of Clausenamide Isomers and Evaluation of Their Potential as Cortical Neuroplastogens
Ou, Y., Khatib, Y. A., Mosswood, A., Roy, T. K., Gutierrez, D. A., Olson, D. E., & Shaw, J. T. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00767 · Cited by 1
Self-citationPsychedelics and longevity: implications for lifespan, healthspan and functional aging
Haden, M., Woods, B., Woods, T., & Tupper, K. W. (2026) · Longevity · doi:10.1080/30653495.2026.2696224 · Cited by 1
Gould, T. D., Mathew, S. J., Fava, M., & Shekhar, A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456206 · Cited by 1
Psilocybin’s effect on human brain synaptic plasticity
Johansen, A., Plavén‐Sigray, P., Madsen, M. K., Søndergaard, A., Messell, C., Geisler, M., Nasser, A., McCulloch, D. E.-W., Beliveau, V., Vassilieva, A., et al. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04285-y · Cited by 1
Stupak, R. (2021) · Praktyka Teoretyczna · doi:10.14746/prt.2021.2.6 · Cited by 1
Kelley, D. P., Venable, K. E., Billac, G. B., Destouni, A., Ebenezer, P. J., Stadler, K., Nichols, C. D., Barker, S. A., & Francis, J. (2021) · Research Square · doi:10.21203/rs.3.rs-602961/v1 · Cited by 1
Kelley, D. P. (2022) · Louisiana State University · doi:10.31390/gradschool_dissertations.5761 · Cited by 1
Gunten, M. V., Russell, T., Stirland, I., Parks, S., Jenkins, T. G., & Edwards, J. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.12.658958 · Cited by 1
GPCR endocytosis rewires neuronal gene expression and cellular architecturePreprint
Hall, K. L., Klauer, M. J., Schexnider, M. E., & Tsvetanova, N. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.26.672159 · Cited by 1
Aharon-Almagor, A., & Barrett, F. S. (2022) · Research Square · doi:10.21203/rs.3.rs-1529935/v1
Translational research investigating psilocybin: underlying neurobiological mechanisms
van den Berg, M. M. J. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230120mb
Chapter 47. Psychedelic Drugs as Treatments in Psychiatry
Nutt, D. J., & Erritzøe, D. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as47
5-HT2AR and its implication on anti-depression therapy development
Chen, Y. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/49/20241282
Shah, R. J., & Sarangi, A. (2025) · Alcoholism Treatment Quarterly · doi:10.1080/07347324.2025.2500345
Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review
de Oliveira, A. L., de Oliveira, D. P., SANTOS, R. G. D., & Hallak, J. E. C. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111534
Changing minds: bioethical dimensions of psychedelic-assisted psychotherapy
Jacobs, E. (2025) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-qq0qxrok6
Murphy, R. J., Godfrey, K., Shaw, A. D., Muthukumaraswamy, S., & Sumner, R. L. (2024) · Figshare · doi:10.6084/m9.figshare.25150540
Šabanović, M., & Lerch, J. P. (2022) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-54xkp76nk
Lane, C. P. (2025) · eScholarship@McGill (McGill) · doi:10.82308/37282
PALMERINI, A. (2025) · Electronic Theses and Dissertations Repository (University of Pisa)
Uso terapeutico delle sostanze psichedeliche
ZUCCHINI, B. (2024) · Electronic Theses and Dissertations Repository (University of Pisa)
Woodruff, S., Hibicke, M., & Nichols, C. D. (2025) · Psychedelic Medicine · doi:10.1177/28314425251393186
Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity
Petrušková, A. (2026) · OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) · doi:10.25593/open-fau-2619
Dolenec, P., Pelčić, G., Pilipović, K., Mršić‐Pelčić, J., & Harej, A. (2026) · Pharmaceuticals · doi:10.3390/ph19020316
Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes
Dwiel, L. L., Prina, M. L., Bragg, E. M., Drucker, L. L., Reduron, L. R., Luikart, B. W., & Doucette, W. T. (2026) · Brain stimulation · doi:10.1016/j.brs.2026.103130
Acute DOI exposure drives cortical hyperexcitability and functional network remodelingPreprint
Haber, I., Bok, I., Kutler, B., Nornberg, M., Banks, M. I., & Hai, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.726129
Kelly, C., Cooley, B. J., Zeng, L., Hurzeler, T. P., Manning, V., McNally, G. P., Watt, J., Haber, P., & Morley, K. C. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106911
Savino, A., Liaci, C., Merlo, G. R., Prandi, L., Avalle, L., & Poli, V. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.11.751070
Jones, J. L., Redding, J., & Amador, E. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261488486
Isotalo, R. (2026) · UTUPub (University of Turku)
AbouEich, H. K., Izadi, A., Lifshitz, J., Olson, D. E., & Gurkoff, G. G. (2026) · Journal of Neurotrauma · doi:10.1177/08977151261495030
Self-citationSmall Molecules Targeting TrkB/BDNF for Neurodegenerative Disease Therapeutic Discovery
Venkatesan, R., Paustian, M. P., Simeon, P., & Trippier, P. C. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00313
Buciuc, A. G., Gold, M. S., & Fuehrlein, B. (2026) · Brain Sciences · doi:10.3390/brainsci16111184
Anchesi, I., Argento, V., Floramo, A., Astorino, M. F., Spinelli, S., Calabrò, M., & Cipriano, G. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms272110010
Metadata
- Authors
- Ly, C., Greb, A. C., Vargas, M. V., Duim, W. C., Grodzki, A. C. G., Lein, P. J., & Olson, D. E.
- Affiliations
- University of California, Davis (US)
- Corresponding author
- Olson, David E.
- ORCID
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-09-11
- Volume
- 4
- Issue
- 2
- Pages
- 452-460
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033616
- OpenAlex
- W3086471578
- Cited by
- 123
- References
- 78
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 19 · 2023: 27 · 2022: 13 · 2021: 14 · 2020: 2
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- University of California, Davis
- National Institutes of Health (1S10OD019980-01A1, R01GM128997, T32GM113770, U54 HD079125)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- psychoplastogens, ketamine, LSD, neuronal atrophy, depression, TrkB signaling, mTOR, AMPA receptors, antidepressants, dendritic spine loss, synaptic density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.